Comparative effectiveness and safety of esketamine versus injectable racemic ketamine and oral antidepressants for major depressive disorder: A population-based target trial emulation
Journal of Affective Disorders · 2026-08 · 406 · 121487
DOI: 10.1016/j.jad.2026.121487 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Affective Disorders, 2026-08. Verfasst von Ching-Hua Julie Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Ketamine, Major Depressive Disorder, Antidepressive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: This study evaluated the long-term comparative effectiveness and safety of esketamine versus injectable ketamine and esketamine versus oral antidepressants for major depressive disorder (MDD). METHODS: This emulated target trial utilized observational data from a cohort of U.S. adults with MDD between 2018 and 2024. Patients were categorized into those receiving esketamine, injectable R,S-ketamine, and those with treatment-resistant depression (TRD) prescribed at least two classes of oral antidepressants. Esketamine initiators were matched to injectable R,S-ketamine initiators and to patients receiving oral antidepressants using propensity scores based on clinical and demographic factors. Outcomes included suicidal ideation or attempt, neuropsychiatric, and cardiovascular outcomes. Cox proportional hazards regression was used to estimate the risk of outcomes. RESULTS: A total of 4505 esketamine initiators, 197,694 injectable R,S-ketamine initiators, and 887,220 patients receiving oral antidepressant were included. After propensity score matching, compared with injectable R,S-ketamine initiators, esketamine initiators were associated with higher risks of suicidal ideation (HR = 1.24, 95% CI = 1.06-1.46), generalized anxiety disorder (HR = 1.55, 95% CI = 1.37-1.74), insomnia (HR = 1.25, 95% CI = 1.07-1.46), and cardiac arrest (HR = 1.57, 95% CI = 1.21-2.20). Compared with patients with TRD receiving oral antidepressants, esketamine initiators were associated with lower risks of suicidal ideation (HR = 0.89, 95% CI = 0.83-0.96), suicide attempt (HR = 0.71, 95% CI = 0.56-0.90), and generalized anxiety disorder (HR = 0.82, 95% CI = 0.74-0.91), but a higher risk of cardiac arrest (HR = 2.09, 95% CI = 1.50-2.91). CONCLUSION: Injectable R,S-ketamine demonstrated a more favorable safety and effectiveness profile than esketamine, whereas esketamine was associated with greater effectiveness but a higher risk of cardiac arrest compared with oral antidepressants. Head-to-head clinical trials are needed to validate these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
- Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA; Department of Psychiatry, Harvard Medical School, Bos…
- Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: kevinskma1@gmail.com.
Zitieren
APA
Lee, C. J., Qian, Y., Yu, W., Cusin, C., & Ma, K. S. (2026). Comparative effectiveness and safety of esketamine versus injectable racemic ketamine and oral antidepressants for major depressive disorder: A population-based target trial emulation. Journal of Affective Disorders, 406, 121487. https://doi.org/10.1016/j.jad.2026.121487
Vancouver
Lee CJ, Qian Y, Yu W, Cusin C, Ma KS. Comparative effectiveness and safety of esketamine versus injectable racemic ketamine and oral antidepressants for major depressive disorder: A population-based target trial emulation. Journal of Affective Disorders. 2026;406:121487. doi:10.1016/j.jad.2026.121487
BibTeX
@article{Lee2026,
author = {Lee, Ching-Hua Julie and Qian, Yunzhe and Yu, Weiqun and Cusin, Cristina and Ma, Kevin Sheng-Kai},
title = {Comparative effectiveness and safety of esketamine versus injectable racemic ketamine and oral antidepressants for major depressive disorder: A population-based target trial emulation},
journal = {Journal of Affective Disorders},
year = {2026},
volume = {406},
pages = {121487},
doi = {10.1016/j.jad.2026.121487}
}
EUVIMED